Pathway‐specific biomarkers, such as the SNCA radiotracer37 for SNCA‐related PD and mitophagy pathway biomarkers for PARK2‐associated patients, might provide opportunities to monitor and evaluate the disease‐modifying effects of antisense therapeutics. The gene discussed is PRKN; the disease is Parkinson disease.